Navigation Links
Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference
Date:8/6/2014

the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, a limited commercial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors cont
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
2. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
3. Venaxis Announces Pricing of Offering of Common Stock and Warrants
4. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
5. Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
6. Intrexon to Present at Jefferies 2014 Global Industrials Conference
7. Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference
8. TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner
9. Dmitry Medvedev Presented BIOCAD the First National "Industry" Award
10. Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness"
11. Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOULDER, Colo. , Jan. 23, 2015  Array BioPharma ... it has reached a definitive agreement with Novartis Pharma ... BRAF inhibitor currently in Phase 3 development.  This agreement is ... and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are ...
(Date:1/22/2015)... 2015 GEA Niro Soavi the leader ... homogenizer, the PandaPLUS 2000, which is ideal for new ... cell disruption . This compact laboratory homogenizer is ... liquid food, food additives and ingredients as well as ...
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... world leader in clinical trial support services, today announced ... located in Austin, TX, is a leader in the ... "True Human" monoclonal antibody into clinical trials. XBiotech,s lead ... being developed to treat diseases such as cancer, atherosclerosis, ...
... ARBOR, Mich., June 2, 2011 Adeona Pharmaceuticals, Inc. ... innovative medicines for serious central nervous system diseases, announced ... clinical study evaluating reaZin along with near-term ... statistical analysis with the Company,s scientific advisors, Adeona intends ...
... June 2, 2011 Sequenom, Inc. (NASDAQ: ... analysis solutions, today announced it and its subsidiary Sequenom ... $30.0 million financing commitment from Silicon Valley Bank’s San ... to support the development and commercialization of new products ...
Cached Biology Technology:C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc 2Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 2Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 3Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 4Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 5Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 6Sequenom Enters Into New $30.0 Million Credit Facility 2Sequenom Enters Into New $30.0 Million Credit Facility 3Sequenom Enters Into New $30.0 Million Credit Facility 4
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... Federal Court of Appeals has overturned an August 2010 ban ... way for broader exploration of how stem cells function and ... of currently incurable diseases. The ruling has been welcomed ... in 2009, and by the nation,s top researchers in the ...
... A gene therapy approach using a protein called CD59, ... age-related macular degeneration (AMD), according to a new in ... Medicine. Led by senior author Rajendra Kumar-Singh, PhD, the ... by a gene therapy approach significantly reduced the uncontrolled ...
... Today, scientists from the California Academy of Sciences will ... in the Philippines, documenting both terrestrial and marine life ... the depths of the sea. They will be joined ... La Salle University, the Philippines National Museum and the ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Gene therapy shows promise against age-related macular degeneration 2California Academy of Sciences launches scientific expedition to the Philippines 2California Academy of Sciences launches scientific expedition to the Philippines 3California Academy of Sciences launches scientific expedition to the Philippines 4California Academy of Sciences launches scientific expedition to the Philippines 5
... GEMINI is Tecan's pipetting software for ... GENESIS Freedom and the GENESIS WORKSTATION instruments ... intuitive software enables the user the simple ... of pipetting scripts. With the powerful scripting ...
Transfection Buffer A & B Set 5 ml each...
...
Intestinal Epithelium Differentiation Environment...
Biology Products: